Wall Street brokerages expect aTyr Pharma Inc (NASDAQ:LIFE) to announce earnings per share of ($0.19) for the current quarter, according to Zacks. Zero analysts have made estimates for aTyr Pharma’s earnings. aTyr Pharma reported earnings per share of ($0.39) during the same quarter last year, which would suggest a positive year over year growth rate of 51.3%. The business is expected to issue its next quarterly earnings results on Monday, March 18th.
On average, analysts expect that aTyr Pharma will report full-year earnings of ($1.13) per share for the current financial year. For the next year, analysts expect that the business will report earnings of ($0.82) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover aTyr Pharma.
aTyr Pharma (NASDAQ:LIFE) last announced its quarterly earnings results on Tuesday, November 13th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.06.
Several research analysts have recently issued reports on LIFE shares. Zacks Investment Research upgraded shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a report on Saturday, November 17th. ValuEngine downgraded shares of aTyr Pharma from a “hold” rating to a “sell” rating in a report on Tuesday, December 18th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $1.01.
Shares of NASDAQ:LIFE traded down $0.02 during trading on Friday, hitting $0.50. 56,513 shares of the company were exchanged, compared to its average volume of 261,725. The company has a market capitalization of $15.76 million, a PE ratio of -0.27 and a beta of 2.43. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.38 and a current ratio of 5.38. aTyr Pharma has a 1-year low of $0.38 and a 1-year high of $3.60.
In related news, Director John Mendlein acquired 245,000 shares of the firm’s stock in a transaction that occurred on Friday, December 21st. The stock was acquired at an average cost of $0.42 per share, for a total transaction of $102,900.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul Schimmel acquired 147,225 shares of the firm’s stock in a transaction that occurred on Monday, November 26th. The stock was bought at an average price of $0.54 per share, with a total value of $79,501.50. The disclosure for this purchase can be found here. Corporate insiders own 25.00% of the company’s stock.
A hedge fund recently raised its stake in aTyr Pharma stock. Renaissance Technologies LLC boosted its stake in aTyr Pharma Inc (NASDAQ:LIFE) by 107.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,107,025 shares of the biotechnology company’s stock after purchasing an additional 573,164 shares during the period. Renaissance Technologies LLC owned about 3.71% of aTyr Pharma worth $899,000 at the end of the most recent reporting period. 37.78% of the stock is owned by institutional investors and hedge funds.
About aTyr Pharma
aTyr Pharma, Inc, a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.
Recommended Story: How to execute a trade ex-dividend strategy?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.